Back روستا آت هوم Arabic Rosetta@home Catalan Rosetta@home Czech Rosetta@home German Rosetta@home Spanish Rosetta@home Finnish Rosetta@home French Rosetta@home Galician Rosetta@home HE Rosetta@home Hungarian

Rosetta@home

Rosetta@home
Developer(s)Baker laboratory, University of Washington; Rosetta Commons
Initial releaseOctober 6, 2005 (2005-10-06)
Stable releaseRosetta: 4.20 / May 1, 2020 (2020-05-01)

Rosetta Mini: 3.78 / October 3, 2017 (2017-10-03)

Rosetta for Android: 4.20 / May 1, 2020 (2020-05-01)
Development statusActive
Operating systemWindows, macOS, Linux, Android
PlatformBOINC
LicenseProprietary freeware for academic and non-profit use,[1]
Average performance225,041 GigaFLOPS[2]
Active users36,726
Total users1,363,584[3]
Active hosts249,673
Total hosts529,112
Websiteboinc.bakerlab.org/rosetta/

Rosetta@home is a volunteer computing project researching protein structure prediction on the Berkeley Open Infrastructure for Network Computing (BOINC) platform, run by the Baker lab. Rosetta@home aims to predict protein–protein docking and design new proteins with the help of about fifty-five thousand active volunteered computers processing at over 487,946 GigaFLOPS on average as of September 19, 2020.[4] Foldit, a Rosetta@home videogame, aims to reach these goals with a crowdsourcing approach. Though much of the project is oriented toward basic research to improve the accuracy and robustness of proteomics methods, Rosetta@home also does applied research on malaria, Alzheimer's disease, and other pathologies.[5]

Like all BOINC projects, Rosetta@home uses idle computer processing resources from volunteers' computers to perform calculations on individual workunits. Completed results are sent to a central project server where they are validated and assimilated into project databases. The project is cross-platform, and runs on a wide variety of hardware configurations. Users can view the progress of their individual protein structure prediction on the Rosetta@home screensaver.

In addition to disease-related research, the Rosetta@home network serves as a testing framework for new methods in structural bioinformatics. Such methods are then used in other Rosetta-based applications, like RosettaDock or the Human Proteome Folding Project and the Microbiome Immunity Project, after being sufficiently developed and proven stable on Rosetta@home's large and diverse set of volunteer computers. Two especially important tests for the new methods developed in Rosetta@home are the Critical Assessment of Techniques for Protein Structure Prediction (CASP) and Critical Assessment of Prediction of Interactions (CAPRI) experiments, biennial experiments which evaluate the state of the art in protein structure prediction and protein–protein docking prediction, respectively. Rosetta consistently ranks among the foremost docking predictors, and is one of the best tertiary structure predictors available.[6]

With an influx of new users looking to participate in the fight against the COVID-19 pandemic, caused by SARS-CoV-2, Rosetta@home has increased its computing power up to 1.7 PetaFlops as of March 28, 2020.[7][8] On September 9, 2020, Rosetta@home researchers published a paper describing 10 potent antiviral candidates against SARS-CoV-2. Rosetta@home contributed to this research and these antiviral candidates are heading towards Phase 1 clinical trials, which may begin in early 2022.[9][10][11][12] According to the Rosetta@home team, Rosetta volunteers contributed to the development of a nanoparticle vaccine.[9] This vaccine has been licensed and is known as the IVX-411 by Icosavax, which began a Phase I/II clinical trial in June 2021,[13] and GBP510 which is being developed by SK Bioscience and is already approved for a Phase III clinical trial in South Korea.[14][15]

NL-201, a cancer drug candidate that was first created at the Institute of Protein Design (IPD) and published in a January 2019 paper,[16] began a Phase 1 Human clinical trial in May 2021 with the support of Neoleukin Therapeutics, itself a spin-off from the IPD.[17] Rosetta@home played a role in the development of NL-201 and contributed with "forward folding" experiments that helped validate protein designs.[18]

  1. ^ "Rosetta@home License Agreement". Boinc.bakerlab.org. Archived from the original on June 12, 2020. Retrieved June 12, 2020.
  2. ^ "Rosetta@home". Archived from the original on April 2, 2023. Retrieved June 18, 2023.
  3. ^ "Rosetta@Home – Detailed stats | BOINCstats/BAM!". Archived from the original on February 11, 2019. Retrieved October 20, 2018.
  4. ^ "Rosetta@home". Archived from the original on March 14, 2016. Retrieved March 24, 2020.
  5. ^ "What is Rosetta@home?". Rosetta@home forums. University of Washington. Archived from the original on September 13, 2008. Retrieved September 7, 2008.
  6. ^ Lensink MF, Méndez R, Wodak SJ (December 2007). "Docking and scoring protein complexes: CAPRI 3rd Edition". Proteins. 69 (4): 704–18. doi:10.1002/prot.21804. PMID 17918726. S2CID 25383642.
  7. ^ "Rosetta@home - Server Status "TeraFLOPS estimate"". Rosetta@home. March 25, 2020. Archived from the original on January 3, 2016. Retrieved March 25, 2020.
  8. ^ "Rosetta@home Rallies a Legion of Computers Against the Coronavirus". HPCWire. March 24, 2020. Archived from the original on April 9, 2020. Retrieved March 25, 2020.
  9. ^ a b "The COVID-19 projects on our platform are headed into human clinical trials! Our amazing online volunteers have played a role in the development of a promising new vaccine as well as candidate antiviral treatments". Twitter. June 25, 2021. Archived from the original on June 26, 2021. Retrieved June 26, 2021.
  10. ^ Cao L, Goreshnik I, Coventry B, Case JB, Miller L, Kozodoy L, et al. (October 2020). "De novo design of picomolar SARS-CoV-2 miniprotein inhibitors". Science. 370 (6515): 426–431. Bibcode:2020Sci...370..426C. doi:10.1126/science.abd9909. PMC 7857403. PMID 32907861.
  11. ^ "Coronavirus update from David Baker. Thank you all for your contributions!". Rosetta@home. September 21, 2020. Archived from the original on October 30, 2020. Retrieved September 23, 2020.
  12. ^ "IPD Annual Report 2021" (PDF). Institute for Protein Design. July 14, 2021. Archived (PDF) from the original on August 18, 2021. Retrieved August 18, 2021.
  13. ^ "ANZCTR - Registration". anzctr.org.au. Archived from the original on October 30, 2021. Retrieved July 9, 2021.
  14. ^ "S. Korea approves Phase III trial of SK Bioscience's COVID-19 vaccine". Reuters. August 10, 2021. Archived from the original on August 18, 2021. Retrieved August 18, 2021.
  15. ^ Institute of Protein Design (August 10, 2021). "Archived copy". Twitter. Archived from the original on August 18, 2021. Retrieved August 18, 2021.{{cite web}}: CS1 maint: archived copy as title (link)
  16. ^ Cite error: The named reference :3 was invoked but never defined (see the help page).
  17. ^ "Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial | Neoleukin Therapeutics, Inc". investor.neoleukin.com. Archived from the original on June 24, 2021. Retrieved June 22, 2021.
  18. ^ "Another publication in Nature describing the first de novo designed proteins with anti-cancer activity". Rosetta@home. January 14, 2020. Archived from the original on October 19, 2020. Retrieved September 19, 2020.

Rich TVX News Network Site

Rich TVX News Network Info

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search